Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: The 78-year-old TV personality tells People magazine he’s responding very well to chemotherapy and the doctors have told him “they hadn’t seen this kind of positive results in their memory.” Trebek says some of the tumors have shrunk by more than 50%. Trebek announced his diagnosis in March, but said he intended to keep working. He said he planned to beat the disease’s low survival rate with the love and support of family and friends and with prayers from viewers. The American Cancer Society estimates 3% of patients with stage 4 pancreatic cancer are alive 5 years after being diagnosed. Trebek says he still has several more rounds of treatment to hopefully get into full remission.
[A]: Alex Trebek shares ‘mind-boggling’ pancreatic cancer update.


[Q]: Developed by Eli Lilly and Co’s (LLY.N) Loxo Oncology and marketed by German drugmaker Bayer (BAYGn.DE), it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. Finding those patients will require widespread adoption of sophisticated tests that look for multiple genetic alterations that could be driving the cancer. So far, progress has been slow. Adoption of so-called next-generation sequencing (NGS) tests has been stalled by lack of reimbursement from insurers over concerns that the evidence is not there yet to support widescale use, according to more than a dozen interviews with oncologists and pharmaceutical and diagnostic industry executives. As a result, pharma companies from small biotech Blueprint Medicines Corp (BPMC.O) to larger rivals Lilly and Roche Holding AG (ROG.S) are taking matters into their own hands, bulking up staff to increase patient and physician awareness about testing and building up a gene testing infrastructure that for many community hospitals still does not exist. Bayer executives told Reuters it plans to spend $70 million to increase patient and physician awareness of testing for rare mutations and to encourage regulatory approval of more tests. They expect that budget to expand as Vitrakvi continues to win approval in other countries. Lilly told Reuters the company has signed an agreement with Thermo Fisher Scientific (TMO.N) to develop a companion diagnostic test for its experimental drug, LOXO-292. The deal adds RET mutations - the target of both Lilly’s and Blueprint’s drugs - to Thermo’s Oncomine Dx Target Test, which local pathology labs can use to identify multiple genes linked with non-small cell lung cancer. The agreement is aimed to help identify more lung and thyroid cancer patients who may benefit from the Lilly or Blueprint therapies. The Thermo test is already approved by the U.S. Food and Drug Administration - a key standard for Medicare coverage, the companies said. According to Dr. Brian Alexander, chief medical officer of Roche’s gene testing company Foundation Medicine, only about 15% of U.S. patients with advanced cancers get comprehensive genomic  profiling. Another 25% get single-gene testing, he said, and a large proportion “are not getting any testing at all.”  At MD Anderson, which sees 100,000 new cancer patients a year, only around 10,000 eventually have their tumors sequenced. For a rare few, the tests are lifesaving. Xin Zheng, 47, a mother of three in Michigan who was referred to Reuters by Blueprint, was diagnosed with stage 4 lung cancer in 2016. After failing several treatments, she was out of options. Her husband, Zhigang Wei, asked for genetic sequencing, and the test turned up a RET mutation. After contacting multiple lung cancer experts, Zhigang found an early-stage clinical trial treating patients with Blueprint’s experimental drug, BLU-677. Now, Xin is nearly back to normal. “My wife is lucky,” he said, adding her quality of life is much better and she has hope for the future. Finding patients with such rare mutations is like “looking for the needle in the haystack,” said Stefan Oelrich, head of pharmaceuticals at Bayer. Dr. David Hyman of Memorial Sloan Kettering Cancer Center, who tested Vitrakvi in clinical trials, said making these tests the norm for advanced cancer patients will require a huge shift in the way oncology is practiced. “It’s painful to know there are patients out there with these alterations who are dying without knowing about it and without getting any treatments,” he said. For Bayer’s Vitrakvi and Roche’s Rozlytrek, along with similar drugs in development, genomic testing is critical to finding patients who can benefit from them. Cancer patients and drug companies alike got a boost last year when the federal Medicare health program for the elderly and disabled said it would cover FDA-approved tests for advanced cancer patients that can identify hundreds of genetic mutations at once. A Medicare endorsement is generally followed by widespread coverage decisions by private insurers. But the final regulations dropped a requirement that testmakers prove the tests are cost-effective and improve patient care. That created an “evidence gap” that has allowed some insurers, also known as third-party payers, to withhold coverage or demand more proof that they benefit patients, said Jeff Schreier of Diaceutics PLC (DXRX.L), a data analytics company that works with drugmakers to improve diagnostic testing. “More payers are coming around, but it’s slow,” he said. The most recent coverage policy from CVS Health Corp’s (CVS.N) Aetna approves many single-gene tests for specific cancers, but still largely considers multi-gene tests experimental. Anthem Inc’s (ANTM.N) policy limits testing to “medically necessary” use and states there’s “insufficient published evidence” to support widespread testing. And while Foundation Medicine’s and Thermo Fisher’s tests are getting reimbursed from Medicare, many hospitals such as MD Anderson, which have developed their own tests, are not guaranteed payment. “Reimbursement is still a driving force,” MD Anderson’s Kenna Shaw said of genomic testing, which costs an average of $5,000 per patient globally. Lilly bought Loxo in January for $8 billion to profit from its targeted drugs in early-stage development. Bayer secured the rights to Loxo’s two leading compounds in a 2017 alliance. Dr. Anthony Sireci, Loxo’s senior medical director, said the company has been working to “democratize” testing in the United States by increasing its use in local pathology labs, where most cancer testing has traditionally been done. The Thermo Fisher agreement will support those goals and expand patients’ access to “high-quality genomic testing,” he said. Bayer has hired diagnostic experts to help its medical and sales staff assess the barriers to genomic testing and ensure that local pathology labs are including the genetic alterations targeted by its drugs when they profile tumors, the company’s oncology strategic business chief Robert LaCaze said in an interview. Bayer also launched a public awareness campaign called “Test Your Cancer” that urges patients to ask their doctors about genomic cancer testing. The company is working with testing providers to ensure test reports are easy to understand. Blueprint, which has six genomically-targeted drugs in development, told Reuters it plans to hire six diagnostics experts to increase awareness of the mutations their drugs target, especially in community medical practices, where 70% of cancers are treated. Bayer sees signs of progress. Based on internal data, the company estimates average sequencing rates across tumors neared 30% last year, and the company saw a two-fold increase in the number of labs offering tests that carry the mutation targeted by Vitrakvi. Bayer has not released sales figures for Vitrakvi. Asked for an update in the most recent earnings call in July, Bayer’s Oelrich said uptake is going “according to plan,” but declined to say how many patients are using the drug. LaCaze said with very rare cancers like the ones Vitrakvi targets, sales growth is “something that will build over time.”
[A]: Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'.


[Q]: Horrifying events like the April 1999 killing of twelve students and a teacher at Columbine High School in Littleton, Colorado, by two of their classmates might have left some believing deadly school shootings were a new ill bestowed upon us by a society only recently gone mad, yet that was not the case. That today’s death tolls are higher and the media coverage surrounding them more intense might serve to encourage belief that this sort of random murder by, and of, young people is a recent phenomenon, but the sad history of such attacks belies that belief. Deadly shooting sprees at schools perpetrated by troubled teens took place at least as much as a generation before Columbine. One of the earliest mass school shootings occurred in 1975 in Ottawa, Canada, when on 27 October of that year, 18-year-old Robert Poulin went on a killing spree at St. Pius X High School, killing one student and wounding five others before turning the gun on himself. Poulin had earlier raped and stabbed a 17-year-old friend to death. Of all the pre-Littleton school shootings, the one most remembered by people at the time was recalled primarily because of its impact on pop culture: it inspired the popular Boomtown Rats song “I Don’t Like Mondays.” Released in October 1979, this song captured the insanity of the moment by working the shooter’s chilling utterance into its lyrics:  Of course fallible memory being what it is, people who now remember the shooting spree behind the song recall it in only the most haphazard of fashions. They recall that a shooting took place at a school, that lives were lost, that the shooter was female, and that by way of explanation for her actions she said “I don’t like Mondays,” but some have her as a high school student gunning down students at her own school, while others remember her as a high school teacher who turned a gun on some of her pupils:  There’s this 80’s song called “I Don’t Like Mondays”. I don’t know who wrote it, but the rumor is that the song was based on a girl. She was a younger girl, I think in High School. She was quiet and was very shy. She didn’t have very many friends. One Monday she went to school with a gun and shot several of her teachers and fellow students. When the cops asked her why she did it she said “I don’t like Mondays”. And that’s what the song was based on. The late 70s/early 80s song “I Don’t Like Mondays” was written to reflect the mindset of a teacher who came to work one day and shot up a schoolyard full of kids. When asked at trial why she did it, the teacher supposedly only gave the reply, “I don’t like Mondays.”  The facts are that on 29 January 1979, 16-year-old Brenda Ann Spencer opened fire on children arriving at Cleveland Elementary School in San Diego from her house across the street, killing two men and wounding eight students and a police officer. Principal Burton Wragg was attempting to rescue children in the line of fire when he was shot and killed, and custodian Mike Suchar was slain attempting to aid Wragg. Spencer used a rifle her father had given her as a gift. As to what impelled her into this form of murderous madness, she told a reporter, “I don’t like Mondays. This livens up the day.” The “Mondays” comment was not the only eyebrow-raising declaration to issue from Spencer that day. According to a report written by the police negotiators who spoke with her during the six-hour standoff, she made comments to them such as: “There was no reason for it, and it was just a lot of fun”; “It was just like shooting ducks in a pond”; and ” [the children] looked like a herd of cows standing around, it was really easy pickings.” That Spencer failed to kill any of the children she shot at was attributable to luck rather than any reluctance on her part to take their lives. The bullet that struck 9-year-old Charles “Cam” Miller missed his heart by about an inch. Spencer pled guilty to two counts of murder and assault with a deadly weapon and was sentenced to 25 years to life in prison. She has been up for parole four times and has been turned down each time, the last in 2005. At her first parole hearing she expressed doubt that any of the victims was hit by bullets from her rifle and contended they might have been shot by police. She also claimed to have been under the influence of alcohol and hallucinogenic drugs at the time of the shootings and asserted prosecutors and her attorney had conspired to fabricate test evidence showing there had been no drugs in her system. By her third parole hearing she was admitting guilt and expressing remorse but was still contending she had been drunk and high on marijuana laced with PCP the day of her deadly rampage. She also claimed something new, that she had been beaten and sexually abused by her father, an avowal conspicuously absent from previous records.
[A]:
"The 1979 Boomtown Rats song ""I Don't Like Mondays"" was inspired by a deadly shooting at a school."